Showing 4261-4270 of 6036 results for "".
- Belkin Vision Announces FDA Clearance for the Eagle for Selective Laser Trabeculoplastyhttps://modernod.com/news/belkin-vision-announces-fda-clearance-for-the-eagle-device/2482005/Belkin Vision has received FDA 510(k) clearance for the Eagle device, a Q-switched, 532 nm-wavelength, frequency-doubled Nd:YAG laser intended for use in performing selective laser trabeculoplasty (SLT). Belkin describes the Eagle as the first and only contactless l
- Optometry Giving Sight Earns Four-Star Rating From Charity Navigatorhttps://modernod.com/news/optometry-giving-sight-earns-four-star-rating-from-charity-navigator/2482001/Optometry Giving Sight (OGS) has announced that its strong financial health and ongoing accountability and transparency have earned a Four-Star rating from Charity Navigator. This rating designates Optometry Giving Sight as an official “Give with Confidence” charity, indicating t
- Zeiss Announces New Biometry Mastery Courses in 2024https://modernod.com/news/zeiss-announces-new-biometry-mastery-courses-in-2024/2482000/Carl Zeiss Meditec is launching the Biometry Mastery Course, a program designed to enhance the skills and expertise of ophthalmic professionals. The Zeiss Biometry Mastery Course is a training initiative aimed at equipping nurses and technicians with advanced knowledge and practica
- Oculis Begins Phase 2b RELIEF Trial of Topical Anti-TNFα Licaminlimab (OCS-02) in Dry Eye Diseasehttps://modernod.com/news/oculis-begins-phase-2b-relief-trial-of-topical-anti-tnfa-licaminlimab-ocs-02-in-dry-eye-disease/2481998/Oculis announced 'First Patient First Visit' (FPFV) in its phase 2b RELIEF trial evaluating the potential of licaminlimab (also known as OCS-02), Oculis’ anti-TNFα biologic eye drop drug candidate for the treatment of dry eye disease (DED). The phase 2b REL
- iHealthScreen Announces MHRA Certification and Registration for iPredict Automated AI Systemhttps://modernod.com/news/ihealthscreen-announces-mhra-certification-and-registration-for-ipredict-automated-ai-system/2481997/iHealthScreen has received UK Medicines and Healthcare Products Regulatory Agency (MHRA) certification and registration for its iPredict AI Eye Screening System, which is used for the early diagnosis of diabetic retinopathy (DR), age-related macular degeneration (AMD), and glaucoma. <
- Horus Pharma Strengthens Its International Expansionhttps://modernod.com/news/horus-pharma-strengthens-its-international-expansion/2481996/Horus Pharma, a France-based provider of preservative-free ophthalmology products, announced it is strengthening its international presence with eight distribution agreements covering Romania, Portugal, Croatia, Turkey, Algeria, Qatar, Ireland, and Bosnia. The deals take
- Nanoscope Therapeutics Names Glenn Sblendorio as Chairman of the Boardhttps://modernod.com/news/nanoscope-therapeutics-names-glenn-sblendorio-as-chairman-of-the-board/2481994/Nanoscope Therapeutics announced the appointment of Glenn Sblendorio as Chairman of the Board, effective immediately. In a news release, Nanoscope said Mr. Sblendorio's comprehensive understanding of finance and business development will assist in guiding N
- Corza Medical Opens Ophthalmology Center of Technology and Innovationhttps://modernod.com/news/corza-medical-opens-ophthalmology-center-of-technology-and-innovation/2481992/Corza Medical announced the opening of its new Ophthalmology Center of Technology and Innovation in St. Louis. The state-of-the-art facility is aimed at advancing the development of next-generation devices for ophthalmic surgeries and other eye treatments. With an approximate footp
- Atsena Therapeutics Announces 12-Month Safety and Efficacy Data from Phase 1/2 Trial of ATSN-101 in Patients with LCA1https://modernod.com/news/atsena-therapeutics-announces-12-month-safety-and-efficacy-data-from-phase-12-trial-of-atsn-101-in-patients-with-lca1/2481991/Atsena Therapeutics announced positive 12-month safety and efficacy data from the ongoing phase 1/2 trial of ATSN-101, the company’s investigational gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). At 12 months post-treatment, ATSN-101 ha
- OliX Pharmaceuticals Announces Safety Data and Preliminary Efficacy Effects in a Phase 1 Trial of OLX10212 for AMDhttps://modernod.com/news/olix-pharmaceuticals-announces-positive-safety-data-and-preliminary-efficacy-effects-in-a-phase-1-trial-of-olx10212-for-age-related-macular-degeneration/2481988/OliX Pharmaceuticals announced positive results from a phase 1 study evaluating the safety and tolerability of OLX10212 for the treatment of age-related macular degeneration (AMD). The development of small interfering RNAs (siRNAs), like OLX10212, which showed efficacy in nonclinical models